文献速递其他结缔组织病

口服seletalisib治疗原发性干燥综合征的2期随机双盲安慰剂对照概念验证研究

A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

因入组困难提前终止,统计效力不足,但观察到ESSDAI和ESSPRI改善趋势,且唾液腺炎症灶大小和组织结构及PI3K-mTOR信号降低。

要点

  • seletalisib 45 mg/日组第12周ESSDAI较安慰剂差异为-2.59(95%CI -7.30, 2.11;P=0.266),呈改善趋势。
  • 唾液腺活检显示seletalisib减少炎症灶大小和组织结构并降低PI3K-mTOR信号。
  • seletalisib组严重不良事件3/13例、因不良事件停药5/13例,均高于安慰剂组。

核心结论

  • 尽管入组困难导致研究提前终止和统计效力丧失,seletalisib在原发性干燥综合征患者中显示出临床改善趋势。
  • 组织学分析显示seletalisib对唾液腺炎症和组织结构有令人鼓舞的作用。

研究设计与样本

  • 2期随机双盲安慰剂对照概念验证研究(NCT02610543),纳入中重度原发性干燥综合征成人患者。
  • 患者按1:1随机接受seletalisib 45 mg/日或安慰剂,并维持现有治疗。

主要发现

  • 第12周ESSDAI较基线变化组间差异为-2.59(95%CI:-7.30, 2.11;P=0.266)。
  • 第12周ESSPRI较基线变化组间差异为-1.55(95%CI:-3.39, 0.28)。
  • 唾液流率和泪液流率未见显著变化。
  • 严重不良事件在seletalisib组为3/13例,安慰剂组为1/14例;因不良事件停药分别为5/13例和1/14例。
  • seletalisib组血清IgM和IgG浓度较安慰剂组下降。

关键数值与推荐

  • 主要终点为安全性和耐受性及第12周ESSDAI较基线变化。
  • 次要终点包括第12周ESSPRI较基线变化和唾液腺活检组织学特征。

临床怎么用

  • 当前证据尚不足以支持seletalisib用于原发性干燥综合征的临床常规治疗。
  • 该研究提示PI3Kδ抑制可能影响唾液腺炎症,需更大样本研究验证。

局限性

  • 研究因入组困难提前终止,统计效力从计划的80%降至36%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This phase 2 proof-of-concept study (NCT02610543) assessed efficacy, safety and effects on salivary gland inflammation of seletalisib, a potent and selective PI3Kδ inhibitor, in patients with moderate-to-severe primary Sjögren's syndrome (PSS). METHODS: Adults with PSS were randomized 1:1 to seletalisib 45 mg/day or placebo, in addition to current PSS therapy. Primary end points were safety and tolerability and change from baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at week 12. Secondary end points included change from baseline at week 12 in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score and histological features in salivary gland biopsies. RESULTS: Twenty-seven patients were randomized (seletalisib n = 13, placebo n = 14); 20 completed the study. Enrolment challenges led to early study termination with loss of statistical power (36% vs 80% planned). Nonetheless, a trend for improvement in ESSDAI and ESSPRI [difference vs placebo: -2.59 (95% CI: -7.30, 2.11; P=0.266) and -1.55 (95% CI: -3.39, 0.28), respectively] was observed at week 12. No significant changes were seen in saliva and tear flow. Serious adverse events (AEs) were reported in 3/13 of patients receiving seletalisib vs 1/14 for placebo and 5/13 vs 1/14 discontinued due to AEs, respectively. Serum IgM and IgG concentrations decreased in the seletalisib group vs placebo. Seletalisib demonstrated efficacy in reducing size and organisation of salivary gland inflammatory foci and in target engagement, thus reducing PI3K-mTOR signalling compared with placebo. CONCLUSION: Despite enrolment challenges, seletalisib demonstrated a trend towards clinical improvement in patients with PSS. Histological analyses demonstrated encouraging effects of seletalisib on salivary gland inflammation and organisation. TRIAL REGISTRATION: https://clinicaltrials.gov, NCT02610543.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Juarez M, Diaz N, Johnston GI, et al. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. Rheumatology (Oxford). 2021. PMID: 32949140. doi:10.1093/rheumatology/keaa410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。